MNG1234
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.457
- ESTROGEN_RESPONSE_EARLY+0.392
- TNFA_SIGNALING_VIA_NFKB+0.381
- ESTROGEN_RESPONSE_LATE+0.325
- APICAL_JUNCTION+0.307
- ANDROGEN_RESPONSE+0.297
- MITOTIC_SPINDLE+0.297
- APICAL_SURFACE+0.291
- ANGIOGENESIS+0.281
- APOPTOSIS+0.278
Top 10 suppressed
- MYC_TARGETS_V2-0.332
- ALLOGRAFT_REJECTION-0.265
- UNFOLDED_PROTEIN_RESPONSE-0.264
- MYC_TARGETS_V1-0.227
- OXIDATIVE_PHOSPHORYLATION-0.152
- MTORC1_SIGNALING-0.133
- E2F_TARGETS-0.067
- PANCREAS_BETA_CELLS-0.029
- SPERMATOGENESIS-0.012
- IL6_JAK_STAT3_SIGNALING+0.003
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-60-2707-01A-01R-0851-07 | — | cohortSQ1 | 0.848 |
| 2 | MNG1059 | — | — | 0.784 |
| 3 | TCGA-GC-A3OO-01A-11R-A22U-07 | — | — | 0.757 |
| 4 | SRR12475109 | — | — | 0.754 |
| 5 | MBCProject_4733_T1_RNA | — | A | 0.754 |
| 6 | SRR12696728 | — | — | 0.754 |
| 7 | 718de66e-06d2-4c2c-8b2d-e40087c4340c | — | — | 0.750 |
| 8 | MNG119 | — | — | 0.749 |
| 9 | TCGA-95-7039-01A-11R-1949-07 | — | cohortA1 | 0.746 |
| 10 | MNG1012 | — | — | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.457 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.392 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.381 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.325 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.307 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.297 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.297 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.291 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.281 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.278 | Idelalisib | — uncovered |
| HYPOXIA | 0.275 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.273 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.239 | Remibrutinib | — uncovered |
| COAGULATION | 0.232 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.228 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.226 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.203 | Idelalisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.187 | Inavolisib | — uncovered |